Business Wire

SOSAFE

24.5.2024 10:41:26 CEST | Business Wire | Press release

Share
SoSafe Introduces The Human Risk OS™, Leading the Category Evolution Towards Human Risk Management

SoSafe, Europe’s largest security awareness and human risk management vendor, has announced the launch of their pioneering Human Risk Operating System, The Human Risk OS™, a set of capabilities designed to help customers identify, quantify, monitor, and intervene on human security risk. SoSafe has also presented new capabilities to its Sofie Human Security Copilot, an AI-powered multi-channel agent built entirely on advanced Large Language Models, as well as incremental updates to its flagship product offering such as next-level personalized learning, behavioral phishing simulation, novel security operations and 3rd party data integrations. With that, SoSafe is leading the category evolution from security awareness to human risk management in response to escalating cyber threats and the need for security strategies to address human risk more holistically.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524947770/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

SoSafe launches The Human Risk OS™, bringing together all of SoSafe’s security offerings into a single cohesive platform that helps security teams to drive a holistic human risk management strategy and foster security cultures. Copyright: SoSafe GmbH

Dr Niklas Hellemann, Psychologist and CEO at SoSafe: “To achieve real risk reduction and meet the demands of security leaders, basic awareness measures alone don’t cut it. While traditional and generic awareness programs focus on awareness and knowledge transfer–educating individuals about potential threats and instructing them on response strategies–this approach often falls short in today’s dynamic environment. The evolving landscape requires an evolution to holistic human risk management, which prioritizes the outcomes and the drivers of behavior and helps to sustainably mitigate human risks.”

The Human Risk OS brings together all of SoSafe’s security offerings into a single cohesive platform that helps security teams to drive a holistic human risk management strategy and foster security cultures. It focuses on proactively managing security risks through real-time risk detection and continuous analyses, provides enhanced behavioural insights and recommends targeted interventions to customize and optimize defensive responses.

Its three core elements are:

  • Human Behavior Sensors measure an organization’s digital activities, behaviors, and security culture, creating individual and group-level profiles of security behavior.
  • The Human Security Index processes this tracked data and additional contextual information such as level of seniority, tenure, digital access, and functional criticality to create a single index that summarizes security performance for groups and organizations. This score allows organizations to quickly identify concern areas, track progress, and evolution over time, and the impact of different possible interventions.
  • The Intervention Hub suggests intervention strategies to mitigate human-related security risks and drive behavioral change and healthy security.

Gonçalo Gaiolas, CPO at SoSafe: “We believe in the power of people in the fight against cybercrime. With The Human Risk OS™, organizations invest in more than just a security solution—they invest in a proactive approach to mitigating human-centric risk and securing their organization's future by putting people at the very center of their efforts. We empower organizations to drive behavioral change and build security cultures by identifying, quantifying, actively managing, and reducing their human risk and by focusing on efficiency to relieve the pressure on overstretched security teams.”

SoSafe also introduced additional capabilities to its “Sofie Human Security Copilot”, an AI-powered multi-channel agent built to meaningfully reduce human risk. Sofie supports security professionals and users with rapid threat awareness, situational awareness, and zero-level security and compliance support. Security leaders can now incorporate organisational policies and specifics into their responses. Built on advanced large language models and featuring an engaging interface, Sofie provides answers to support questions at any time, sends urgent security alerts, and educates users on security best practices, all customized to specific organizational needs and policies.

Unlike other conversational AI-solutions, Sofie focuses on making each interaction with the end user a learning moment in their daily work environment, not just delivering informative content, but also aiming to change behavior.

Gonçalo Gaiolas: “Cybercriminals are already harnessing the power of AI to enhance their social engineering attacks. It's time to use the full potential of AI on the defensive side as well. Our AI-powered multi-channel agent ‘Sofie’ demonstrates the power of AI for cyber defenses: It’s a multifunctional tool that makes security information accessible to everyone anytime, provides learning opportunities in every interaction, and supports security administrators with content and communication, automating responses to free up their team’s capacity. ‘Sofie’ makes cybersecurity part of our everyday work, manifesting security cultures as the most essential part of holistic human risk management.”

Ilona Simpson, longstanding CIO and Executive Advisor at SoSafe: “SoSafe’s Human Risk OS™ and Sofie help security leaders to efficiently drive a human risk management strategy that sustainably mitigates risk. Based on behavioral data and fueled with new technology, SoSafe simplifies where others complicate, making it easy for security professionals to strengthen the human layer as the most versatile part of our defense strategy. SoSafe's focus on automation and efficiency not only saves security teams significant time but also amplifies their results, enhancing overall security posture.”

SoSafe presented its product innovations “The Human Risk OS™” and “Sofie Human Security Copilot” with its new capabilities during a launch event on May 23rd in Cologne, Germany and via livestream in front of more than 300 industry guests.

About SoSafe

SoSafe, founded by a team of behavioral scientists and technology experts, is the largest security awareness and human risk management vendor based in Europe. SoSafe is empowering over 4700 customers worldwide to effectively mitigate cyber risk. With a unique human-centric approach grounded in behavioral science, SoSafe enhances secure behavior across organizations, making it intuitive and second nature. The platform is designed to strengthen digital self-defense by creating robust security cultures that actively involve employees in mitigating human risks. By leveraging psychology and advanced technology and AI, it enables security professionals to effectively identify, prioritize, manage, and ultimately reduce their human risk. The SoSafe team now consists of more than 450 employees in seven locations: Cologne (headquarters), Amsterdam, Berlin, London, Paris, Lisbon, and Munich.

Website: www.sosafe-awareness.com/
LinkedIn: www.linkedin.com/company/sosafe-cyber-security/mycompany/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240524947770/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 07:00:00 CEST | Press release

The ruling confirms that Beerenberg did not infringe Aspen Aerogels’ patents. The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. Th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye